Innocoll Securities Litigation
October 28, 2022. The Court in the Innocoll securities matter (Eastern District of Pennsylvania) approved a class action settlement in the amount of $2.755 million. Plaintiff alleged that defendants concealed risks relating to the likelihood that the company’s pain management drug XaraColl would receive FDA approval. Plaintiffs retained Crowninshield Financial Research to provide expert analysis […]
Puma Biotechnology Securities Litigation
August 3, 2022. The Court in the Puma Biotechnology securities matter (Central District of California) approved a class action settlement in the amount of $54.2 million. The settlement followed a 2019 federal jury trial that resulted in the jury finding Puma Biotechnology guilty of securities fraud. Plaintiffs alleged that Puma Biotechnology made false and misleading […]
Merit Medical Securities Litigation
April 18, 2022. The Court approved Merit Medical’s $18.25 million payment to end a securities class action lawsuit that was brought against the company in the Central District of California. Plaintiffs alleged that Merit Medical misled investors about the company’s business and prospects; specifically, Merit Medical’s integration of two acquisitions was disastrous and the company’s […]
Jeld-Wen Securities Litigation
November 22, 2021. The Court in the Jeld-Wen securities matter (Eastern District of Virginia) approved a $40 million class action settlement and plan of allocation. Plaintiffs alleged that Jeld-Wen failed to disclose its intentional anticompetitive conduct that violated federal antitrust law. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert analysis and testimony on […]
Restoration Robotics Securities Litigation
September 9, 2021. The Court approved a $4.175 million settlement and plan of allocation to resolve all claims in the Restoration Robotics securities class action lawsuit (Northern District of California San Jose Division). Plaintiff alleged that Restoration Robotics made materially false and misleading statements in the registration statement and prospectus for the company’s initial public […]
WageWorks Securities Litigation
August 20, 2021. The Court approved a $30 million settlement to end a securities class action lawsuit that was brought against WageWorks in the U.S. District Court for the Northern District of California. Plaintiffs alleged that WageWorks improperly recognized revenue and falsely attested to the effectiveness of its internal controls over financial reporting. Crowninshield Financial […]
Sociedad Química y Minera Securities Litigation
April 26, 2021. The Court approved a $62.5 million settlement to end a securities class action lawsuit that was brought against SQM in the U.S. District Court for the Southern District of New York. Plaintiffs alleged, among other things, that SQM issued materially false and misleading statements regarding the Company’s failure to disclose that money […]
The Southern Company Securities Litigation
February 5, 2021. The Court in The Southern Company securities matter (Northern District of Georgia Atlanta Division) approved an $87.5 million settlement for the benefit of the Class of Southern common stock investors. Plaintiffs alleged that Southern misled investors regarding the construction timeline of a “clean coal” power plant. Professor Steven Feinstein of Babson College […]
Acer Therapeutics Securities Litigation
January 7, 2022. The Court in the Acer Therapeutics securities matter (Southern District of New York) approved a class action settlement in the amount of $8.35 million. Plaintiffs alleged that Acer misled investors about the true likelihood of and timeline for FDA approval of the company’s drug to treat vascular Ehlers-Danlos Syndrome. Plaintiffs retained Crowninshield […]
Novo Nordisk Securities Litigation
September 24, 2021. Novo Nordisk agreed to pay $100 million to end a securities class action lawsuit that was brought against the company in the District Court of New Jersey. Plaintiffs alleged that Novo Nordisk made material misrepresentations and omissions about factors that impacted Novo Nordisk’s U.S. diabetes business segment. Professor Steven Feinstein of Babson […]
